In two new papers, both published in Cell Reports Medicine, researchers from the University of Michigan Rogel Cancer Center describe聽the mechanisms of how alterations in the CDK12 gene drive prostate cancer development and report聽on a promising degrader that targets CDK12 and a related gene to destroy tumors.
Pregnant people are bombarded with advice about how to keep their future children healthy. While parents worry about nutritional supplements and exercise, one aspect is less often discussed: how paternal reproductive health can be an indicator for the health of their children and, perhaps surprisingly, the rest of the family.
As head of Counseling Services at UA Little Rock, Dr. Aresh Assadi has counseled many college students during his 13 years at the university, but there is one question that has often plagued him early on in his career. Why do so few male college students seek counseling when compared to women?
People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy 鈥� proton beam therapy or intensity modulated radiation therapy (IMRT) 鈥� achieved equally high rates of tumor control with no differences in patient-reported quality of life, according to a first-of-its-kind phase III clinical trial comparing the two technologies. Findings of the PARTIQoL trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
In addition to the studies featured on the press program (details here) for the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting, the following studies were recommended by ASTRO experts and may be of interest to journalists.
This special edition features advances in radiation therapy approaches presented by MD Anderson researchers at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting. Information on all MD Anderson ASTRO Annual Meeting content can be found at MDAnderson.org/ASTRO.
The annual meeting will feature 23 abstracts from UCLA investigators that highlight key areas of radiation oncology, including new research in subspecialties ranging from survivorship, lung cancer/thoracic malignancies, physics, sarcoma, gastrointestinal cancer, genitourinary cancer, gynecological cancer, pediatric cancer and diversity, equity and inclusion in healthcare.
Microboost technology -- a leading-edge approach to targeted radiation treatment for prostate cancer -- will be the topic of Dr. Brandon Mahal's Presidential Symposium presentation next week at the American Society for Radiation Oncology (ASTRO) meeting.
A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery following androgen deprivation therapy in men undergoing radiotherapy for prostate cancer, providing key insights for optimizing patient care.
Hackensack Meridian Health鈥檚 Men鈥檚 Health Day Offers Screenings for Those at High Risk for Prostate Cancer & Other Diseases
In a multisite randomized controlled trial published in JAMA Network Open in September 2024, the use of Ceevra 3D models in robotic prostatectomy procedures were shown to reduce risk of cancer recurrence, improve functional outcomes, and improve rates of trifecta outcomes.
Dr. Jeremie Calais received two grants from Novartis totaling $4 million aimed at improving the effectiveness of the radiation-emitting targeted therapy 177-Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC), one of the most challenging forms of the disease.
By tracking the changes in prostate cancer cells over time, researchers at the Johns Hopkins Kimmel Cancer Center have found that activation of the MYC gene 鈥� a well-known cancer-causing gene 鈥� sets off a cascade of events that leads to both initiation and progression of the disease.
A grant from the National Institutes of Health will support ongoing research at Wayne State University investigating the consequences environmental factors may have on fertility in males.
On the morning of Wednesday, September 4, 2024, Hackensack Meridian Hackensack University Medical Center became the first hospital in the world to treat patients with Aquablation庐 therapy using the new HYDROS鈩� Robotic System.
As prescription oral chemotherapies have become a common form of cancer treatment, some patients were paying more than $10,000 a year for medications. A new study finds that efforts to cap prescription drug spending are yielding significant out-of-pocket savings for these patients.
Researchers at the University of Michigan Health Rogel Cancer Center have uncovered a key reason why a typically normal protein goes awry and fuels cancer. They found the protein NSD2 alters the function of the androgen receptor, an important regulator of normal prostate development.
The American Society for Radiation Oncology (ASTRO) announced today the seven studies to be highlighted in the 2024 ASTRO Annual Meeting press program. Researchers will discuss their findings in news briefings held September 30 and October 1 at the Walter E. Washington Convention Center in Washington, D.C. and via live webcast.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 欧美极品 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right